Your session is about to expire
← Back to Search
Immunotherapy + Chemotherapy for Small Cell Lung Cancer (CASPIAN Trial)
CASPIAN Trial Summary
This trial is testing a new combination treatment for small-cell lung cancer as compared to standard chemotherapy.
CASPIAN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCASPIAN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129CASPIAN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread widely, and any brain metastases are stable without needing steroids or anti-convulsants for over a month.I am eligible for platinum-based chemotherapy as my first treatment.I have not had treatments that boost the body's natural defenses to fight cancer, except for cancer vaccines.My cancer has spread widely, and any brain metastases are stable without needing steroids or anti-convulsants for 1 month.I am fully active or restricted in physically strenuous activity but can do light work.I have not had treatments that boost the body's natural defenses to fight cancer, except for cancer vaccines.I am eligible for platinum-based chemotherapy as my first treatment.I do not have active infections like TB, HIV, or hepatitis.I am fully active or restricted in physically strenuous activity but can do light work.I have had or will have chest radiation before or after systemic therapy.I have a condition related to my cancer that affects other parts of my body and needs treatment.I do not have any uncontrolled illnesses like lung disease.I have or had an autoimmune or inflammatory disorder.You have a life expectancy ≥12 weeks at Day 1.\n\n
- Group 1: Arm 1
- Group 2: Arm 2
- Group 3: Arm 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants being enrolled in this experiment right now?
"No, this particular research study is not currently looking for more participants. Although, according to the latest update on September 26th, 2022, it is inactive, there are 5531 other trials that are recruiting."
Does this research include elderly citizens as test subjects?
"According to the inclusion criteria found on clinicaltrials.gov, people between 18-130 years old may apply for this particular trial. Out of the 5644 total clinical trials, 287 are for patients under 18 and 5357 are for patients 65 and older."
Why did researchers initiate this clinical trial?
"The primary objective of this trial, as measured over a period of approximately 33 months, is overall survival. This will be assessed at an interim analysis and compared between the durvalumab + epacadostat + pembrolizumab group and the epacadostat + pembrolizumab group. Other secondary outcomes being assessed include the number of patients with an ADA response to durvalumab, time to deterioration of global health status/HRQoL, and change from baseline in primary PRO symptoms."
For what sorts of conditions is Durvalumab most often prescribed?
"Hodgkin disease is one of many conditions treatable by Durvalumab. This medication can also target other issues like malignant pleural mesothelioma, advanced head and neck cancer, and advance directives."
In how many different medical institutions is this clinical trial being overseen?
"There are presently 20 sites running this particular clinical trial. The locations are based in Muncie, Birmingham and Nashville along with other locations 20 other locations. It is helpful to select the clinic closest you to minimize travel demands if you enroll."
Has Durvalumab received approval from the Federal Drug Administration?
"There is both existing efficacy data and multiple rounds of safety data, so Durvalumab was given a score of 3."
Who does this clinical trial apply to?
"This study is looking for 987 people with carcinoma that meet the age requirements of 18-130. The most important requirements are as follows: a histological or cytological documentation of extensive disease, brain metastases that are asymptomatic or have been treated and have been stable for at least a month prior to study treatment, the ability to receive a platinum-based chemotherapy regimen, a life expectancy of at least 12 weeks, an ECOG score of 0 or 1, and no prior exposure to immune-mediated therapy with the exception of therapeutic anticancer vaccines."
With what other drugs has Durvalumab been tested in previous clinical trials?
"City of Hope Comprehensive Cancer Center was the first institution to study durvalumab, back in 1997. As of now, there have been 2020 completed studies and 1588 active clinical trials. A large portion of these trials take place in Muncie, Indiana."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger